Most Ditch GLP-1 Drugs for Weight Loss Within a Year
Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
The dark side of weight loss drugs no one warns about
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these popular medications.
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Hosted on MSN3d
Think Beyond GLP-1: True Weight Loss Requires More
GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...
Wellness, GLP-1 weight loss drugs and the Super Bowl—behind the emerging trend
Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.
Josh Gad Reveals Weight Loss From GLP-1 Medication, Changing Relationship With Food
GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...
WPSD Local 61h
The benefits and risks of GLP-1 drugs
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
Oprah Winfrey shares experience of taking ‘magic drug’ GLP-1 for weight loss: ‘One of the first things I realised…’
American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
MM&M6d
Hims & Hers set for Super Bowl ad debut highlighting GLP-1 weight loss drugs
Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.